Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired Cl-inhibitor deficiencies

被引:57
作者
Cugno, M [1 ]
Cicardi, M [1 ]
Coppola, R [1 ]
Agostoni, A [1 ]
机构
[1] UNIV MILAN,INST INTERNAL MED,I-20122 MILAN,ITALY
来源
IMMUNOPHARMACOLOGY | 1996年 / 33卷 / 1-3期
关键词
hereditary angioedema; acquired angioedema; factor XII; high molecular weight kininogen; kinin;
D O I
10.1016/0162-3109(96)00086-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hereditary and acquired Cl-inhibitor (Cl-INH) deficiencies (hereditary angioedema, HAE and acquired angioedema, AAE) are characterized by episodic increases in vasopermeability due to kinin release. Despite continuously defective Cl-INH levels, symptoms only recur occasionally suggesting an episodic generation of pathogenetic factors induced by activation of the protease systems regulated by Cl-INH. We evaluated activation of factor XII by measuring plasma levels of FXIIa with a commercial ELISA and cleavage of high molecular weight kininogen by performing SDS PAGE and immunoblotting analysis during 5 attacks in 5 different patients with HAE and during 7 attacks in 3 patients with AAE. The patients were also studied during remission. We confirmed our previous data indicating that during attacks both HAE and AAE patients had very high levels of cleaved HK (p < 0.0001) whereas during remission cleaved HK levels were normal in HAE and significantly increased in AAE (p < 0.0001). Both in HAE and in AAE, plasma levels of FXIIa were normal during remission and significantly increased during acute attacks (p = 0.0126; p = 0.0003). Our data suggest that the activation of a contact system is required to produce clinical symptoms.
引用
收藏
页码:361 / 364
页数:4
相关论文
共 10 条
[1]   HEREDITARY AND ACQUIRED C1-INHIBITOR DEFICIENCY - BIOLOGICAL AND CLINICAL CHARACTERISTICS IN 235 PATIENTS [J].
AGOSTONI, A ;
CICARDI, M .
MEDICINE, 1992, 71 (04) :206-215
[2]  
BOISCLAIR MD, 1993, BLOOD, V82, P3350
[3]   ACTIVATION OF THE CONTACT SYSTEM AND FIBRINOLYSIS IN AUTOIMMUNE ACQUIRED ANGIOEDEMA - A RATIONALE FOR PROPHYLACTIC USE OF TRANEXAMIC ACID [J].
CUGNO, M ;
CICARDI, M ;
AGOSTONI, A .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (05) :870-876
[4]  
CUGNO M, 1993, J LAB CLIN MED, V121, P38
[5]   C1 INHIBITOR AND HEREDITARY ANGIONEUROTIC-EDEMA [J].
DAVIS, AE .
ANNUAL REVIEW OF IMMUNOLOGY, 1988, 6 :595-628
[6]  
de la Cadena RA, 1994, HEMOSTASIS THROMBOSI, P219
[7]  
KAUFMAN N, 1991, BLOOD, V77, P2660
[8]  
KLENIEWSKI J, 1992, J LAB CLIN MED, V120, P129
[9]  
SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22
[10]   DEMONSTRATION OF MODIFIED INACTIVE 1ST COMPONENT OF COMPLEMENT (C1) INHIBITOR IN THE PLASMAS OF C1 INHIBITOR-DEFICIENT PATIENTS [J].
ZURAW, BL ;
CURD, JG .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (02) :567-575